These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 10765092)

  • 1. Quality of life of patients with newly diagnosed poor prognosis M1 prostate cancer undergoing orchiectomy without or with mitomycin C. Results from the EORTC Phase-III trial 30893.
    Fosså SD; Curran D; Aaronson NK; Keuppens F; Kliment J; Robinson MR; DeReijke TM; Hetherington J; Kil PJ; Rea LA
    Eur Urol; 2000 May; 37(5):541-51. PubMed ID: 10765092
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Orchiectomy and orchiectomy plus mitomycin C for metastatic prostate cancer in patients with poor prognosis: the final results of a European Organization for Research in Cancer Therapy Genitourinary Group Trial.
    de Reijke TM; Keuppens FI; Whelan P; Kliment J; Robinson MR; Rea LA; Sylvester RJ
    J Urol; 1999 Nov; 162(5):1658-64; discussion 1664-5. PubMed ID: 10524892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitomycin C for metastatic prostate cancer: final analysis of a randomized trial.
    Boel K; Van Poppel H; Goethuys H; Derluyn J; Vandenbroucke F; Popelier G; Casselman J; Billiet I; Vanuytsel L; Paridaens R; Baert L
    Anticancer Res; 1999; 19(3B):2157-61. PubMed ID: 10472324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline quality of life of patients with advanced prostate cancer. European Organization for Research and Treatment of Cancer (EORTC), Genito-Urinary Tract Cancer Cooperative Group (GUT-CCG).
    Curran D; Fossa S; Aaronson N; Kiebert G; Keuppens F; Hall R
    Eur J Cancer; 1997 Oct; 33(11):1809-14. PubMed ID: 9470838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interim results on a randomized trial of mitomycin C in combination with orchidectomy for newly diagnosed metastatic prostate cancer.
    Vandenbroucke F; Van Poppel H; Derluyn J; Popelier G; Casselman J; Billiet I; Vanuytsel L; Paridaens R; Baert L
    Am J Clin Oncol; 1995 Jun; 18(3):263-6. PubMed ID: 7747716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mitomycin C in combination with orchiectomy for newly diagnosed metastatic prostate cancer: preliminary results on a randomized trial.
    Van Poppel H; van den Broucke F; Derluyn J; Popelier G; Casselman J; Billiet I; van Uytsel L; Paridaens R; Baert L
    J Urol; 1993 Jun; 149(6):1485-7. PubMed ID: 8501794
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The quality of life of patients with newly diagnosed M1 prostate cancer: experience with EORTC clinical trial 30853.
    da Silva FC; Fossa SD; Aaronson NK; Serbouti S; Denis L; Casselman J; Whelan P; Hetherington J; Fava C; Richards B; Robinson MR
    Eur J Cancer; 1996 Jan; 32A(1):72-7. PubMed ID: 8695246
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoblastic flare assessed by serum alkaline phosphatase activity is an index of short duration of response in prostate cancer patients with bone metastases submitted to systemic therapy.Gruppo Onco Urologico Piemontese (G.O.U.P).
    Berruti A; Cerutti S; Fasolis G; Sperone P; Tarabuzzi R; Bertetto O; Pagani G; Zolfanelli R; Pallotti S; Bumma C; Fontana D; Rosseti SR; Dogliotti L; Angeli A
    Anticancer Res; 1997; 17(6D):4697-702. PubMed ID: 9494591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCG+MMC trial: adding mitomycin C to BCG as adjuvant intravesical therapy for high-risk, non-muscle-invasive bladder cancer: a randomised phase III trial (ANZUP 1301).
    Hayne D; Stockler M; McCombie SP; Chalasani V; Long A; Martin A; Sengupta S; Davis ID
    BMC Cancer; 2015 May; 15():432. PubMed ID: 26014129
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of urological morbidity on quality of life in patients with prostate cancer.
    Fosså SD; Woehre H; Kurth KH; Hetherington J; Bakke H; Rustad DA; Skånvik R
    Eur Urol; 1997; 31 Suppl 3():3-8. PubMed ID: 9101208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality-of-Life Analysis of the German Prospective Multicentre Trial of Single-cycle Adjuvant BEP Versus Retroperitoneal Lymph Node Dissection in Clinical Stage I Nonseminomatous Germ Cell Tumours.
    Flechtner HH; Fischer F; Albers P; Hartmann M; Siener R;
    Eur Urol; 2016 Mar; 69(3):518-25. PubMed ID: 26620368
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of adjuvant chemotherapy in the long-term outcome of patients with resected gastric cancer.
    Grau JJ; Martín M; Fuster J; Pera M; García-Valdecasas JC; Bombí JA; Bordas JM; Alcobendas F; Grande L; Estapé J
    J Surg Oncol; 2003 Apr; 82(4):234-40. PubMed ID: 12672007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
    Maisey N; Chau I; Cunningham D; Norman A; Seymour M; Hickish T; Iveson T; O'Brien M; Tebbutt N; Harrington A; Hill M
    J Clin Oncol; 2002 Jul; 20(14):3130-6. PubMed ID: 12118027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health-related quality of life in early breast cancer.
    Groenvold M
    Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevention of bladder tumours after nephroureterectomy for primary upper urinary tract urothelial carcinoma: a prospective, multicentre, randomised clinical trial of a single postoperative intravesical dose of mitomycin C (the ODMIT-C Trial).
    O'Brien T; Ray E; Singh R; Coker B; Beard R;
    Eur Urol; 2011 Oct; 60(4):703-10. PubMed ID: 21684068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
    Tannock IF; Osoba D; Stockler MR; Ernst DS; Neville AJ; Moore MJ; Armitage GR; Wilson JJ; Venner PM; Coppin CM; Murphy KC
    J Clin Oncol; 1996 Jun; 14(6):1756-64. PubMed ID: 8656243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-cultural application of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire for patients with prostate cancer - EORTC QLQ-PR25.
    Park J; Shin DW; Yun SJ; Park SW; Jeon SS; Kwak C; Kwon TG; Kim HJ; Ahn H
    Oncology; 2013; 85(5):299-305. PubMed ID: 24217330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Higher sexual interest with androgen receptor inhibitor monotherapy than with castration plus an androgen receptor inhibitor in prostate cancer patients treated with curative radiotherapy, but otherwise small health-related quality of life differences: A randomised prospective 18-month follow-up study.
    Majumder K; Nilsson S; Johansson H; Ullén A; Lennernäs B; Bergenmar M; Brandberg Y
    Eur J Cancer; 2016 Sep; 65():43-51. PubMed ID: 27459586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of docetaxel-based chemotherapy on quality of life of patients with castration-resistant prostate cancer: results from a prospective phase II randomized trial.
    Caffo O; Sava T; Comploj E; Fariello A; Zustovich F; Segati R; Sacco C; Veccia A; Galligioni E
    BJU Int; 2011 Dec; 108(11):1825-32. PubMed ID: 21615854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone.
    Osoba D; Tannock IF; Ernst DS; Neville AJ
    J Clin Oncol; 1999 Jun; 17(6):1654-63. PubMed ID: 10561201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.